Stop missing eligible patients. Our AI delivers eligibility alerts directly in physician workflows with zero training required, driving 2x enrollment speed and $60M+ operational savings per trial.
Monthly encounters
Accuracy across 9 sites
Enrollment improvement
85% of clinical trials face significant delays due to recruitment challenges. Every month of delay equals millions in lost revenue and delayed access to life-changing therapies. Current solutions rely on manual chart review, creating bottlenecks that are slow and inconsistent.
Chart review takes hours per patient, creating bottlenecks that delay enrollment
Inconsistent screening leads to expensive failures and regulatory delays
Mid-trial amendments due to poor recruitment waste millions in development costs
Recruitment delays push back market entry and competitive advantage
Real-time EHR integration delivers eligibility alerts directly inside physician workflows with zero training required. Pre-visit screening ensures no eligible patients slip through the cracks.
AI reads and understands unstructured clinical notes, imaging reports, and lab values as physicians document care
Simultaneously evaluate patients against multiple trial protocols, maximizing enrollment opportunities
Enterprise-grade security with role-based access controls and cloud-native architecture
Our physician-developed AI is trained on diverse clinical scenarios and seamlessly integrates with your trial workflows.
Identify eligible patients in real-time as clinical data is documented. Never miss an eligible patient again and 2x recruitment speed.
Simultaneously evaluate patients against multiple trial protocols, maximizing enrollment opportunities and optimizing site efficiency.
Advanced analytics provide enrollment forecasting and site performance insights to optimize trial planning and execution.
Cosign AI is powered by our Retina Intelligence engine, trained by retina specialists on diverse clinical circumstances. Our solutions seamlessly integrate with your trial workflows and clinical practice.
Published evidence from Retinal Diagnostic Center across 728 consecutive patient records.
Single-site validation study
Across 3 AMD trial protocols
Average processing time
Retina Society 2025: "Feasibility of AI-Assisted Screening for Clinical Trials in Wet Age-Related Macular Degeneration"
728 consecutive patients from etinal Diagnostic Center across LUGANO/LUCIA, ASCENT, and CONSTANCE trials.
View Full StudyCONSTANCE: 98.8% accuracy, 100% sensitivity
ASCENT: 96.6% accuracy, 83.3% sensitivity
LUGANO: 95.8% accuracy, 80.7% sensitivity
"I was delighted to see patients flagged who I would have otherwise missed. Cosign AI provides a non-intrusive reminder about eligible patients while I am seeing them, enabling me to think about appropriate studies for my patients in the midst of my busy clinic."
Built by physicians for pharmaceutical-grade security, compliance, and scalability.
Enterprise-grade encryption and audit trails
Scalable infrastructure on Google Cloud and Microsoft Azure platforms
Seamless integration with Epic, Athena, Nextech, and other major EHR systems
Granular permissions for sponsors, CROs, sites, and investigators
Understands complex medical terminology and unstructured clinical notes
Instant analysis as clinical data is entered into EHR systems